{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:18:26Z","timestamp":1772648306838,"version":"3.50.1"},"reference-count":181,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PEst-OE\/SAU\/ UI0776\/2014; PTDC\/DTP-PIC\/1308\/2014; PTDC\/MED-GEN\/28245\/2017; UID\/DTP\/00776\/2013\/POCI-01-0145-FEDER-006868; CEECINST\/00091\/2018"],"award-info":[{"award-number":["PEst-OE\/SAU\/ UI0776\/2014; PTDC\/DTP-PIC\/1308\/2014; PTDC\/MED-GEN\/28245\/2017; UID\/DTP\/00776\/2013\/POCI-01-0145-FEDER-006868; CEECINST\/00091\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Centre of Portuguese Oncology Institute of Porto (CI-IPOP)","award":["CI-IPOP-16-2012"],"award-info":[{"award-number":["CI-IPOP-16-2012"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Prostate cancer (PrCa) ranks among the top five cancers for both incidence and mortality worldwide. A significant proportion of PrCa susceptibility has been attributed to inherited predisposition, with 10\u201320% of cases expected to occur in a hereditary\/familial context. Advances in DNA sequencing technologies have uncovered several moderate- to high-penetrance PrCa susceptibility genes, most of which have previously been related to known hereditary cancer syndromes, namely the hereditary breast and ovarian cancer (BRCA1, BRCA2, ATM, CHEK2, and PALB2) and Lynch syndrome (MLH1, MSH2, MSH6, and PMS2) genes. Additional candidate genes have also been suggested, but further evidence is needed to include them in routine genetic testing. Recommendations based on clinical features, family history, and ethnicity have been established for more cost-efficient genetic testing of patients and families who may be at an increased risk of developing PrCa. The identification of alterations in PrCa predisposing genes may help to inform screening strategies, as well as treatment options, in the metastatic setting. This review provides an overview of the genetic basis underlying hereditary predisposition to PrCa, the current genetic screening recommendations, and the implications for clinical management of the disease.<\/jats:p>","DOI":"10.3390\/ijms21145036","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:22:02Z","timestamp":1594981322000},"page":"5036","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-1543","authenticated-orcid":false,"given":"Andreia","family":"Brand\u00e3o","sequence":"first","affiliation":[{"name":"Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"given":"Paula","family":"Paulo","sequence":"additional","affiliation":[{"name":"Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5982","authenticated-orcid":false,"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal"},{"name":"Department of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal"},{"name":"Biomedical Sciences Institute Abel Salazar (ICBAS), University of Porto, 4200-072 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"a030361","DOI":"10.1101\/cshperspect.a030361","article-title":"The epidemiology of prostate cancer","volume":"8","author":"Pernar","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_2","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1177\/1557988318798279","article-title":"Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location","volume":"12","author":"Taitt","year":"2018","journal-title":"Am. J. Men\u2019s Heal."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1634\/theoncologist.2009-0132","article-title":"Age at Diagnosis and Age at Death in Familial Prostate Cancer","volume":"14","author":"Brandt","year":"2009","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/560857","article-title":"Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent","volume":"2013","author":"Rebbeck","year":"2013","journal-title":"Prostate Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1750-9378-4-S1-S2","article-title":"Prostate cancer disparities in Black men of African descent: A comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa","volume":"4","author":"Odedina","year":"2009","journal-title":"Infectious Agents Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)35617-3","article-title":"Hereditary Prostate Cancer: Epidemiologic and Clinical Features","volume":"150","author":"Carter","year":"1993","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdr056","article-title":"Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer","volume":"23","author":"Brandt","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rogers, L.Q., Courneya, K.S., Paragi-Gururaja, R., Markwell, S.J., and Imeokparia, R. (2008). Lifestyle behaviors, obesity, and perceived health among men with and without a diagnosis of prostate cancer: A population-based, cross-sectional study. BMC Public Health, 8.","DOI":"10.1186\/1471-2458-8-23"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/01635581.2011.539311","article-title":"Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer","volume":"63","author":"John","year":"2011","journal-title":"Nutr. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1743-7075-11-30","article-title":"Prostate cancer and the influence of dietary factors and supplements: A systematic review","volume":"11","author":"Mandair","year":"2014","journal-title":"Nutr. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdy073","article-title":"Physical activity in relation to risk of prostate cancer: A systematic review and meta-analysis","volume":"29","author":"Benke","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/aja.2011.150","article-title":"The role of BRCA1 and BRCA2 in prostate cancer","volume":"14","author":"Castro","year":"2012","journal-title":"Asian J. Androl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","article-title":"Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"50","author":"Schumacher","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ng.3094","article-title":"A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer","volume":"46","author":"Berndt","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/ijc.32525","article-title":"A genome-wide association study of prostate cancer in Latinos","volume":"146","author":"Du","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1038\/ncomms9469","article-title":"Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21393","DOI":"10.18632\/oncotarget.7250","article-title":"A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population","volume":"7","author":"Marzec","year":"2016","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1038\/s41467-019-12267-6","article-title":"12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population","volume":"10","author":"Takata","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/oxfordjournals.epirev.a000789","article-title":"Familial Prostate Cancer","volume":"23","author":"Stanford","year":"2001","journal-title":"Epidemiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/CEJ.0000000000000101","article-title":"Contribution of shared environmental factors to familial aggregation of common cancers","volume":"24","author":"Sundquist","year":"2015","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial Risk and Heritability of Cancer among Twins in Nordic Countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.20892\/j.issn.2095-3941.2016.0002","article-title":"Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing","volume":"13","author":"Stanislaw","year":"2016","journal-title":"Cancer Boil. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","article-title":"Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?","volume":"31","author":"Domchek","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jmoldx.2017.05.001","article-title":"Validation of a Next-Generation Sequencing Pipeline for the Molecular Diagnosis of Multiple Inherited Cancer Predisposing Syndromes","volume":"19","author":"Paulo","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated Risk of Prostate Cancer among Men With Lynch Syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/gim.2013.193","article-title":"Prostate cancer incidence in males with Lynch syndrome","volume":"16","author":"Haraldsdottir","year":"2014","journal-title":"Genet. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10689-015-9832-x","article-title":"The role of germline mutations in the BRCA1\/2 and mismatch repair genes in men ascertained for early-onset and\/or familial prostate cancer","volume":"15","author":"Maia","year":"2015","journal-title":"Fam. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline Mutations inHOXB13and Prostate-Cancer Risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.molcel.2009.10.020","article-title":"The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens","volume":"36","author":"Norris","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1055-9965.EPI-12-0495","article-title":"Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer","volume":"21","author":"Breyer","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1055-9965.EPI-12-1000-T","article-title":"HOXB13 G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk","volume":"22","author":"Laitinen","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.eururo.2013.03.007","article-title":"Germline Homeobox B13 (HOXB13) G84E Mutation and Prostate Cancer Risk in European Descendants: A Meta-analysis of 24 213 Cases and 73 631 Controls","volume":"64","author":"Shang","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10897-013-9672-5","article-title":"Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer","volume":"23","author":"Handorf","year":"2013","journal-title":"J. Genet. Couns."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mdv004","article-title":"Prevalence of theHOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes","volume":"26","author":"Mikropoulos","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_38","first-page":"5","article-title":"HOXB13 is a susceptibility gene for prostate cancer: Results from the International Consortium for Prostate Cancer Genetics (ICPCG)","volume":"132","author":"Xu","year":"2012","journal-title":"Qual. Life Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1055-9965.EPI-15-0247","article-title":"The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies","volume":"24","author":"Hathcock","year":"2015","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/carcin\/bgt055","article-title":"The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: Results from the REDUCE trial","volume":"34","author":"Chen","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pros.22552","article-title":"A novel Germline mutation inHOXB13is associated with prostate cancer risk in Chinese men","volume":"73","author":"Lin","year":"2012","journal-title":"Prostate"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Maia, S., Cardoso, M., Pinto, P., Pinheiro, M., Santos, C., Peixoto, A., Bento, M.J., Oliveira, J., Henrique, R., and Jer\u00f3nimo, C. (2015). Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132728"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-Analysis of BRCA1 and BRCA2 Penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2017.07.004","article-title":"Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers","volume":"84","author":"Lee","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3892\/or.2013.2541","article-title":"Hereditary breast and ovarian cancer susceptibility genes","volume":"30","author":"Kobayashi","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: Different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2014","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2018.0271","article-title":"Malignant Abnormalities in Male BRCA Mutation Carriers","volume":"4","author":"Mano","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10689-011-9506-2","article-title":"Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations","volume":"11","author":"Moran","year":"2011","journal-title":"Fam. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/bjc.2012.146","article-title":"Germline BRCA1 mutations increase prostate cancer risk","volume":"106","author":"Leongamornlert","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00006254-200301000-00016","article-title":"Cancer Incidence in BRCA1 Mutation Carriers","volume":"58","author":"Thompson","year":"2003","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients","volume":"105","author":"Collaborators","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Breast Cancer Linkage Consortium Cancer Risks in BRCA2 Mutation Carriers","volume":"91","author":"Easton","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.bjc.6603929","article-title":"Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer","volume":"97","author":"Agalliu","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/345310","article-title":"Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene","volume":"72","author":"Edwards","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1940-6207.CAPR-10-0397","article-title":"Decreased Prostate Cancer-Specific Survival of Men with BRCA2 Mutations from Multiple Breast Cancer Families","volume":"4","author":"Thorne","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc3878","article-title":"Milestones of Lynch syndrome: 1895\u20132015","volume":"15","author":"Lynch","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"14755","DOI":"10.1038\/ncomms14755","article-title":"Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2","volume":"8","author":"Haraldsdottir","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.296.12.1469","article-title":"Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome","volume":"296","author":"Stockwell","year":"2006","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer Risks for PMS2-Associated Lynch Syndrome","volume":"36","author":"Broeke","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1897-4287-11-9","article-title":"Germline deletions in the EPCAM gene as a cause of Lynch syndrome \u2013 literature review","volume":"11","author":"Tutlewska","year":"2013","journal-title":"Hered. Cancer Clin. Pr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10689-012-9591-x","article-title":"EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients","volume":"12","author":"Ligtenberg","year":"2012","journal-title":"Fam. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ijc.23508","article-title":"The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome","volume":"123","author":"Watson","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajmg.a.20106","article-title":"Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum","volume":"121","author":"Soravia","year":"2003","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1158\/1055-9965.EPI-09-0058","article-title":"Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer","volume":"18","author":"Grindedal","year":"2009","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L","article-title":"Cancer risk in mutation carriers of DNA-mismatch-repair genes","volume":"81","author":"Aarnio","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10689-012-9534-6","article-title":"Cancer spectrum in DNA mismatch repair gene mutation carriers: Results from a hospital based Lynch syndrome registry","volume":"11","author":"Pande","year":"2012","journal-title":"Fam. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1200\/JCO.2012.43.2278","article-title":"Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome","volume":"30","author":"Engel","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2005.03.7333","article-title":"Genotype-Phenotype Comparison of German MLH1 and MSH2 Mutation Carriers Clinically Affected With Lynch Syndrome: A Report by the German HNPCC Consortium","volume":"24","author":"Goecke","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1038\/sj.onc.1210872","article-title":"Activation and regulation of ATM kinase activity in response to DNA double-strand breaks","volume":"26","author":"Lee","year":"2007","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM Mutations in Cancer: Therapeutic Implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer","volume":"29","author":"Cybulski","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","article-title":"PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS","volume":"53","author":"Southey","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.ejca.2011.03.025","article-title":"Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility","volume":"47","author":"Xiang","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","article-title":"Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study","volume":"34","author":"Nordestgaard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/sj.bjc.6601425","article-title":"CHEK2 variants associate with hereditary prostate cancer","volume":"89","author":"Ikonen","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1086\/346094","article-title":"Mutations in CHEK2 Associated with Prostate Cancer Risk","volume":"72","author":"Dong","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/bjc.2012.486","article-title":"An inherited NBN mutation is associated with poor prognosis prostate cancer","volume":"108","author":"Cybulski","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Paulo, P., Maia, S., Pinto, C., Pinto, P., Monteiro, A., Peixoto, A., and Teixeira, M.R. (2018). Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset\/familial prostate cancer. PLoS Genet., 14.","DOI":"10.1371\/journal.pgen.1007355"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Rantapero, T., Wahlfors, T., K\u00e4hler, A., Hultman, C., Lindberg, J., Tammela, T.L.J., Nykter, M., Schleutker, J., and Wiklund, F. (2020). Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. Genes, 11.","DOI":"10.3390\/genes11030314"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cub.2009.02.018","article-title":"PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response","volume":"19","author":"Zhang","year":"2009","journal-title":"Curr. Boil."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ng1947","article-title":"Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer","volume":"39","author":"Reid","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene","volume":"39","author":"Rahman","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.1171202","article-title":"Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1002\/cncr.30817","article-title":"Germline genetic variants in men with prostate cancer and one or more additional cancers","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature05609","article-title":"A recurrent mutation in PALB2 in Finnish cancer families","volume":"446","author":"Erkko","year":"2007","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Horak, P., Weischenfeldt, J., Von Amsberg, G., Beyer, B., Schutte, A., Uhrig, S., Gieldon, L., Klink, B., Feuerbach, L., and H\u00fcbschmann, D. (2019). Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Mol. Case Stud., 5.","DOI":"10.1101\/mcs.a003657"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0092-8674(01)00304-X","article-title":"BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function","volume":"105","author":"Cantor","year":"2001","journal-title":"Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/ng1902","article-title":"Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles","volume":"38","author":"Seal","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Ramus, S.J., Song, H., Dicks, E., Tyrer, J.P., Rosenthal, A.N., Intermaggio, M.P., Fraser, L.S.M., Gentry-Maharaj, A., Hayward, J., and Philpott, S. (2015). Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J. Natl. Cancer Inst., 107.","DOI":"10.1093\/jnci\/djv214"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/sj.bjc.6604847","article-title":"A recurrent truncating germline mutation in the BRIP1\/FANCJ gene and susceptibility to prostate cancer","volume":"100","author":"Jugurnauth","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0092-8674(00)81174-5","article-title":"Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome","volume":"93","author":"Varon","year":"1998","journal-title":"Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1158\/0008-5472.CAN-03-2502","article-title":"NBS1 is a prostate cancer susceptibility gene","volume":"64","author":"Cybulski","year":"2004","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41416-018-0141-7","article-title":"Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease","volume":"119","author":"Saunders","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.bjc.6602007","article-title":"ATM polymorphisms as risk factors for prostate cancer development","volume":"91","author":"Falconer","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","article-title":"Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13","volume":"61","author":"Easton","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/294575","article-title":"CHEK2 \u22171100delC Mutation and Risk of Prostate Cancer","volume":"2014","author":"Hale","year":"2014","journal-title":"Prostate Cancer"},{"key":"ref_112","first-page":"15708","article-title":"CHEK2 mutation and risk of prostate cancer: A systematic review and meta-analysis","volume":"8","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.eururo.2012.07.027","article-title":"A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk","volume":"65","author":"Karlsson","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","article-title":"Risk of Prostate Cancer in Lynch Syndrome: A Systematic Review and Meta-analysis","volume":"23","author":"Ryan","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Stopsack, K.H., Nandakumar, S., Wibmer, A.G., Haywood, S., Weg, E.S., Barnett, E.S., Kim, C.J., Carbone, E.A., Vasselman, S.E., and Nguyen, B. (2020). Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-20-0168"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","article-title":"Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide","volume":"74","author":"Antonarakis","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Nguyen-Dumont, T., MacInnis, R.J., Steen, J.A., Theys, D., Tsimiklis, H., Hammet, F., Mahmoodi, M., Pope, B.J., Park, D.J., and Mahmood, K. (2020). Rare germline genetic variants and risk of aggressive prostate cancer. Int. J. Cancer.","DOI":"10.1002\/ijc.33024"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10689-014-9744-1","article-title":"High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry","volume":"13","author":"Rosty","year":"2014","journal-title":"Fam. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-019-0127-1","article-title":"Benefits and limitations of genome-wide association studies","volume":"20","author":"Tam","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1746-4811-9-29","article-title":"The advantages and limitations of trait analysis with GWAS: A review","volume":"9","author":"Korte","year":"2013","journal-title":"Plant Methods"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/ng.3785","article-title":"Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer","volume":"49","author":"Milne","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-019-09775-w","article-title":"Association analyses identify 31 new risk loci for colorectal cancer susceptibility","volume":"10","author":"Law","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/1055-9965.EPI-16-1046","article-title":"A Review of Prostate Cancer Genome-Wide Association Studies (GWAS)","volume":"27","author":"Benafif","year":"2018","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1055-9965.EPI-12-0598","article-title":"Evaluating genetic risk for prostate cancer among Japanese and Latinos","volume":"21","author":"Cheng","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/ng.839","article-title":"Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21","volume":"43","author":"Haiman","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.635","article-title":"Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population","volume":"42","author":"Takata","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/ijc.29066","article-title":"Generalizability of established prostate cancer risk variants in men of African ancestry","volume":"136","author":"Han","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1038\/s41467-018-06863-1","article-title":"Germline variation at 8q24 and prostate cancer risk in men of European ancestry","volume":"9","author":"Matejcic","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.juro.2011.09.011","article-title":"Risk Loci on Chromosome 8q24 are Associated With Prostate Cancer in Northern Chinese Men","volume":"187","author":"Liu","year":"2012","journal-title":"J. Urol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.1073\/pnas.0903103106","article-title":"Potential etiologic and functional implications of genome-wide association loci for human diseases and traits","volume":"106","author":"Hindorff","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"54616","DOI":"10.18632\/oncotarget.10520","article-title":"Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer","volume":"7","author":"Jin","year":"2016","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Farashi, S., Kryza, T., and Batra, J. (2020). Pathway Analysis of Genes Identified through Post-GWAS to Underpin Prostate Cancer Aetiology. Genes, 11.","DOI":"10.3390\/genes11050526"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ng.2862","article-title":"A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding","volume":"46","author":"Huang","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1093\/hmg\/ddt086","article-title":"Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression","volume":"22","author":"Saunders","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41568-018-0087-3","article-title":"Post-GWAS in prostate cancer: From genetic association to biological contribution","volume":"19","author":"Farashi","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/humu.22909","article-title":"Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites","volume":"37","author":"Bu","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng.3523","article-title":"Gene regulatory mechanisms underpinning prostate cancer susceptibility","volume":"48","author":"Whitington","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_140","first-page":"549","article-title":"A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact","volume":"35","author":"MacInnis","year":"2011","journal-title":"Genet. Epidemiology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1055-9965.EPI-15-0543","article-title":"Genome-wide association study of prostate cancer-specific survival","volume":"24","author":"Szulkin","year":"2015","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"145","DOI":"10.6004\/jnccn.2010.0010","article-title":"The 2010 NCCN Clinical Practice Guidelines in Oncology on Prostate Cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fgene.2018.00624","article-title":"A Systematic Review of the Psychological Implications of Genetic Testing: A Comparative Analysis Among Cardiovascular, Neurodegenerative and Cancer Diseases","volume":"9","author":"Oliveri","year":"2018","journal-title":"Front. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10689-016-9890-8","article-title":"Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications","volume":"15","author":"Snyder","year":"2016","journal-title":"Fam. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/gim.2012.167","article-title":"Incorporating genomics into breast and prostate cancer screening: Assessing the implications","volume":"15","author":"Chowdhury","year":"2013","journal-title":"Genet. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urology.2017.03.030","article-title":"Intraductal Carcinoma of the Prostate: A Risk for Rapid Recurrence","volume":"105","author":"Dinerman","year":"2017","journal-title":"Urology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.23484","article-title":"Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","volume":"78","author":"Velho","year":"2018","journal-title":"Prostate"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","article-title":"Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis","volume":"67","author":"Risbridger","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrurol.2014.91","article-title":"Prostate cancer in young men: An important clinical entity","volume":"11","author":"Salinas","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/pros.21414","article-title":"Early onset prostate cancer has a significant genetic component","volume":"72","author":"Lange","year":"2011","journal-title":"Prostate"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/jmg.26.12.799","article-title":"Practical Genetic Counselling","volume":"26","author":"Harris","year":"1989","journal-title":"J. Med. Genet."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3343\/alm.2018.38.4.291","article-title":"Principles of Genetic Counseling in the Era of Next-Generation Sequencing","volume":"38","author":"Yang","year":"2018","journal-title":"Ann. Lab. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.23739","article-title":"Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing","volume":"79","author":"Giri","year":"2018","journal-title":"Prostate"},{"key":"ref_154","unstructured":"National Comprehensive Cancer Network (2020, June 05). NCCN Clinical Practice Guidelines in Oncology\u2014Prostate Cancer Early Detection, Version 2. Available online: www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf."},{"key":"ref_155","unstructured":"European Association of Urology (2020, June 05). Prostate Cancer. Available online: https:\/\/uroweb.org\/guideline\/prostate-cancer\/."},{"key":"ref_156","unstructured":"American Cancer Society (2020, June 05). American Cancer Society Recommendations for Prostate Cancer Early Detection. Available online: https:\/\/www.cancer.org\/cancer\/prostate-cancer\/detection-diagnosis-staging\/acs-recommendations.html."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative Clinical Genomics of Advanced Prostate Cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline Mutations in ATM and BRCA1\/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death","volume":"71","author":"Na","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/bjc.2014.428","article-title":"The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer","volume":"111","author":"Akbari","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations","volume":"76","author":"Marshall","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","year":"2018","journal-title":"DNA Repair"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","article-title":"High speed of fork progression induces DNA replication stress and genomic instability","volume":"559","author":"Moudry","year":"2018","journal-title":"Nature"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1093\/nar\/gkn403","article-title":"PARP inhibition versus PARP-1 silencing: Different outcomes in terms of single-strand break repair and radiation susceptibility","volume":"36","author":"Godon","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Livraghi, L., and Garber, J.E. (2015). PARP inhibitors in the management of breast cancer: Current data and future prospects. BMC Med., 13.","DOI":"10.1186\/s12916-015-0425-1"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1\/2 Mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1389450118666170711151518","article-title":"PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials","volume":"19","author":"Kamel","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"viii272","DOI":"10.1093\/annonc\/mdy284.002","article-title":"Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations","volume":"29","author":"Abida","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/cncr.30808","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","volume":"123","author":"Pomerantz","year":"2017","journal-title":"Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2018.09.048","article-title":"Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency","volume":"75","author":"Zafeiriou","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17512433.2018.1464388","article-title":"PD-1\/PD-L1 pathway inhibitors in advanced prostate cancer","volume":"11","author":"Velho","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2018.13152","article-title":"Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing","volume":"320","author":"Mersch","year":"2018","journal-title":"JAMA"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"7Turner, S.A., Rao, S.K., Morgan, R.H., Vnencak-Jones, C.L., and Wiesner, G.L. (2018). The impact of variant clasification on the clinical management of hereditary cancer syndromes. Genet. Med., 21, 426\u2013430.","DOI":"10.1038\/s41436-018-0063-z"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jmoldx.2014.10.004","article-title":"Reporting incidental findings in genomic scale clinical sequencing--a clinical laboratory perspective: A report of the Association for Molecular Pathology","volume":"17","author":"Hegde","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): A policy statement of the American College of Medical Genetics and Genomics","volume":"19","author":"Kalia","year":"2016","journal-title":"Genet. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/5036\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:12Z","timestamp":1760176152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/5036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":181,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["ijms21145036"],"URL":"https:\/\/doi.org\/10.3390\/ijms21145036","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}